FDA’s Drug Center Reorganization Creates Second Safety Director Position
Executive Summary
The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety
You may also be interested in...
FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff
FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities
FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff
FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development